Estrogen receptor regulation of quinone reductase in breast cancer: implications for estrogen-induced breast tumor growth and therapeutic uses of tamoxifen.

Monica M. Montano, Nicole R. Bianco, Huayun Deng, Bryan M. Wittmann, Laura C. Chaplin, Benita S Katzenellenbogen

Research output: Contribution to journalReview article

Abstract

Antiestrogens have found widespread use in the treatment of breast cancer (reviewed in ref. 1). There is also interest in the use of tamoxifen as a preventive agent for breast cancer. However, the mechanism for the antitumor effects of antiestrogens is relatively unknown. For the most part it is thought that the basis for the anticancer action of antiestrogens is the inhibition of estradiol (E2)-stimulated tumor growth. We have observed however that antiestrogens can activate detoxifying enzymes, like quinone reductase (NQO1), which protect cells against the toxic and tumor-promoting effects of carcinogens (2). Studies characterizing the molecular mechanisms behind the regulation of NQO1 by the Estrogen Receptor (ER) support an important role of the ER in pathways regulating antioxidant defenses. Moreover these findings represent a novel mechanism through which antiestrogens function. The activation of NQO1 may contribute to the beneficial anticancer and antioxidant activity of antiestrogens in breast cancer and possibly other estrogen target tissues. It is possible that the basis for some of the anticancer action of antiestrogens is that the induction of NQO1 inhibits the genotoxic effects induced by the oxidative metabolism of estrogens.

Original languageEnglish (US)
Pages (from-to)1440-1461
Number of pages22
JournalFrontiers in bioscience : a journal and virtual library
Volume10
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

NAD(P)H Dehydrogenase (Quinone)
Estrogen Receptor Modulators
Therapeutic Uses
Tamoxifen
Estrogen Receptors
Tumors
Estrogens
Breast Neoplasms
Growth
Antioxidants
Poisons
Metabolism
Carcinogens
Estradiol
Neoplasms
Chemical activation
Tissue
Enzymes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Estrogen receptor regulation of quinone reductase in breast cancer : implications for estrogen-induced breast tumor growth and therapeutic uses of tamoxifen. / Montano, Monica M.; Bianco, Nicole R.; Deng, Huayun; Wittmann, Bryan M.; Chaplin, Laura C.; Katzenellenbogen, Benita S.

In: Frontiers in bioscience : a journal and virtual library, Vol. 10, 2005, p. 1440-1461.

Research output: Contribution to journalReview article

@article{1e3f1bca9e9a4aaca661ce6b8160f40c,
title = "Estrogen receptor regulation of quinone reductase in breast cancer: implications for estrogen-induced breast tumor growth and therapeutic uses of tamoxifen.",
abstract = "Antiestrogens have found widespread use in the treatment of breast cancer (reviewed in ref. 1). There is also interest in the use of tamoxifen as a preventive agent for breast cancer. However, the mechanism for the antitumor effects of antiestrogens is relatively unknown. For the most part it is thought that the basis for the anticancer action of antiestrogens is the inhibition of estradiol (E2)-stimulated tumor growth. We have observed however that antiestrogens can activate detoxifying enzymes, like quinone reductase (NQO1), which protect cells against the toxic and tumor-promoting effects of carcinogens (2). Studies characterizing the molecular mechanisms behind the regulation of NQO1 by the Estrogen Receptor (ER) support an important role of the ER in pathways regulating antioxidant defenses. Moreover these findings represent a novel mechanism through which antiestrogens function. The activation of NQO1 may contribute to the beneficial anticancer and antioxidant activity of antiestrogens in breast cancer and possibly other estrogen target tissues. It is possible that the basis for some of the anticancer action of antiestrogens is that the induction of NQO1 inhibits the genotoxic effects induced by the oxidative metabolism of estrogens.",
author = "Montano, {Monica M.} and Bianco, {Nicole R.} and Huayun Deng and Wittmann, {Bryan M.} and Chaplin, {Laura C.} and Katzenellenbogen, {Benita S}",
year = "2005",
doi = "10.2741/1630",
language = "English (US)",
volume = "10",
pages = "1440--1461",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-4715",
publisher = "Frontiers in Bioscience",

}

TY - JOUR

T1 - Estrogen receptor regulation of quinone reductase in breast cancer

T2 - implications for estrogen-induced breast tumor growth and therapeutic uses of tamoxifen.

AU - Montano, Monica M.

AU - Bianco, Nicole R.

AU - Deng, Huayun

AU - Wittmann, Bryan M.

AU - Chaplin, Laura C.

AU - Katzenellenbogen, Benita S

PY - 2005

Y1 - 2005

N2 - Antiestrogens have found widespread use in the treatment of breast cancer (reviewed in ref. 1). There is also interest in the use of tamoxifen as a preventive agent for breast cancer. However, the mechanism for the antitumor effects of antiestrogens is relatively unknown. For the most part it is thought that the basis for the anticancer action of antiestrogens is the inhibition of estradiol (E2)-stimulated tumor growth. We have observed however that antiestrogens can activate detoxifying enzymes, like quinone reductase (NQO1), which protect cells against the toxic and tumor-promoting effects of carcinogens (2). Studies characterizing the molecular mechanisms behind the regulation of NQO1 by the Estrogen Receptor (ER) support an important role of the ER in pathways regulating antioxidant defenses. Moreover these findings represent a novel mechanism through which antiestrogens function. The activation of NQO1 may contribute to the beneficial anticancer and antioxidant activity of antiestrogens in breast cancer and possibly other estrogen target tissues. It is possible that the basis for some of the anticancer action of antiestrogens is that the induction of NQO1 inhibits the genotoxic effects induced by the oxidative metabolism of estrogens.

AB - Antiestrogens have found widespread use in the treatment of breast cancer (reviewed in ref. 1). There is also interest in the use of tamoxifen as a preventive agent for breast cancer. However, the mechanism for the antitumor effects of antiestrogens is relatively unknown. For the most part it is thought that the basis for the anticancer action of antiestrogens is the inhibition of estradiol (E2)-stimulated tumor growth. We have observed however that antiestrogens can activate detoxifying enzymes, like quinone reductase (NQO1), which protect cells against the toxic and tumor-promoting effects of carcinogens (2). Studies characterizing the molecular mechanisms behind the regulation of NQO1 by the Estrogen Receptor (ER) support an important role of the ER in pathways regulating antioxidant defenses. Moreover these findings represent a novel mechanism through which antiestrogens function. The activation of NQO1 may contribute to the beneficial anticancer and antioxidant activity of antiestrogens in breast cancer and possibly other estrogen target tissues. It is possible that the basis for some of the anticancer action of antiestrogens is that the induction of NQO1 inhibits the genotoxic effects induced by the oxidative metabolism of estrogens.

UR - http://www.scopus.com/inward/record.url?scp=33748657632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748657632&partnerID=8YFLogxK

U2 - 10.2741/1630

DO - 10.2741/1630

M3 - Review article

C2 - 15769636

AN - SCOPUS:33748657632

VL - 10

SP - 1440

EP - 1461

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-4715

ER -